These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1448131)

  • 21. As easy as ESAP. The New York State Expanded Syringe Access Demonstration Program.
    Shotsky WJ; Cooper JG; Klein SJ
    Body Posit; 2003; 16(1):15-7. PubMed ID: 12739507
    [No Abstract]   [Full Text] [Related]  

  • 22. Deregulation of the sale and possession of syringes for HIV prevention among injection drug users.
    Vlahov D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):71-2. PubMed ID: 7648287
    [No Abstract]   [Full Text] [Related]  

  • 23. [The HIV-epidemic among drug addicts in Norway].
    Aavitsland P; Nilsen O; Lystad A
    Tidsskr Nor Laegeforen; 1996 Nov; 116(29):3502-5. PubMed ID: 9019859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh?
    Foss AM; Watts CH; Vickerman P; Azim T; Guinness L; Ahmed M; Rodericks A; Jana S
    Addiction; 2007 Jan; 102(1):114-25. PubMed ID: 17207129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Residual injection risk behavior, HIV infection, and the evaluation of syringe exchange programs.
    Des Jarlais DC; Braine N; Yi H; Turner C
    AIDS Educ Prev; 2007 Apr; 19(2):111-23. PubMed ID: 17411414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continued risky injection subsequent to syringe exchange use among injection drug users in New York City.
    Paone D; Des Jarlais DC; Caloir S; Jose B; Shi Q; Friedman SR
    AIDS Educ Prev; 1997 Dec; 9(6):505-10. PubMed ID: 9451478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users.
    Bluthenthal RN; Ridgeway G; Schell T; Anderson R; Flynn NM; Kral AH
    Addiction; 2007 Apr; 102(4):638-46. PubMed ID: 17286637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Misuse of syringes--clean syringes should limit the harm. Interview by Jesper Berg].
    Legêne L; Fich C
    Sygeplejersken; 1997 Sep; 97(39):10-1. PubMed ID: 9393076
    [No Abstract]   [Full Text] [Related]  

  • 29. Structural impediments to operational syringe-exchange programs.
    Heimer R; Bluthenthal RN; Singer M; Khoshnood K
    AIDS Public Policy J; 1996; 11(4):169-84. PubMed ID: 10915251
    [No Abstract]   [Full Text] [Related]  

  • 30. [ESAP. More access to syringes].
    Caceres W
    Sidahora; 2005; ():18-21. PubMed ID: 16634158
    [No Abstract]   [Full Text] [Related]  

  • 31. In eastern Connecticut, IDUs purchase syringes from pharmacies but don't carry syringes.
    Grund JP; Heckathorn DD; Broadhead RS; Anthony DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):104-5. PubMed ID: 7648280
    [No Abstract]   [Full Text] [Related]  

  • 32. Syringe exchange schemes: a report and some commentaries.
    Br J Addict; 1989 Nov; 84(11):1283-90. PubMed ID: 2597805
    [No Abstract]   [Full Text] [Related]  

  • 33. Survival of HIV-1 in syringes.
    Abdala N; Stephens PC; Griffith BP; Heimer R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):73-80. PubMed ID: 9928733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Following the blood: syringe reuse leads to blood-borne virus transmission among injection drug users.
    Koester S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 18 Suppl 1():S139-40. PubMed ID: 9663637
    [No Abstract]   [Full Text] [Related]  

  • 35. Detection of infectious human immunodeficiency type 1 virus in discarded syringes of intravenous drug users.
    Zamora AB; Rivera MO; García-Algar O; Caylà Buqueras J; Vall Combelles O; García-Sáiz A
    Pediatr Infect Dis J; 1998 Jul; 17(7):655-7. PubMed ID: 9686738
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV incidence among needle exchange participants: estimates from syringe tracking and testing data.
    Kaplan EH; Heimer R
    J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):182-9. PubMed ID: 8301530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of needle and syringe combinations.
    Zule WA; Ticknor-Stellato KM; Desmond DP; Vogtsberger KN
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Mar; 14(3):294-5. PubMed ID: 9117464
    [No Abstract]   [Full Text] [Related]  

  • 38. Measuring HIV-1 infection among needle/syringe exchange attenders.
    Green ST; Goldberg DJ; Frischer M; Cameron S; Taylor A; Gruer L
    Am J Med; 1995 Jun; 98(6):596-8. PubMed ID: 7778578
    [No Abstract]   [Full Text] [Related]  

  • 39. Isolation of HIV-1 from experimentally contaminated multidose local anaesthetic vials.
    Druce JD; Locarnini SA; Birch CJ
    Med J Aust; 1995 May; 162(10):513-5. PubMed ID: 7776910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV infection and needle-stick injuries with syringes discarded by drug abusers.
    Rinaldi R; Francavilla E; Cadrobbi P; Bortolotti F
    Infection; 1991; 19(1):57. PubMed ID: 2013512
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.